Eric Shaff, Seres Therapeutics CEO
FDA sets Seres on the priority review path for its microbiome C. difficile drug, setting up April decision
Though several companies have been looking at new drugs and candidates to go after C. difficile, one biotech is at the FDA’s doorstep.
Seres Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
